Li Ka Shing Faculty of Medicine

Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

Retrieved on: 
Tuesday, July 18, 2023
Seniors, Biotechnology, Pharmaceutical, Optical, General Health, Health, Consumer, Clinical Trials, Glaucoma, Abstract, ARVO, Li Ka Shing Faculty of Medicine, NR, Eye, Control, NAD, UCL Institute of Ophthalmology, Research, ChromaDex, Trial of the century, School of Clinical Medicine, University of Cambridge, Medicine, Moorfields Eye Hospital, Patient, Peripheral vision, Randomness, School, Investigative Ophthalmology & Visual Science, Optic nerve, Association for Research in Vision and Ophthalmology, Regulatory affairs, Medical device, Medical imaging, Ophthalmology

Together, the promising results from these abstracts suggest that glaucoma patients have lower cellular NAD+ levels and thus replenishing NAD+ levels with a precursor, such as nicotinamide riboside (NR), may be a potential therapeutic strategy.

Key Points: 
  • Together, the promising results from these abstracts suggest that glaucoma patients have lower cellular NAD+ levels and thus replenishing NAD+ levels with a precursor, such as nicotinamide riboside (NR), may be a potential therapeutic strategy.
  • Dr. Garway-Heath’s abstract titled “ Primary open angle glaucoma patients have lower systemic mitochondrial function, associated with lower systemic nicotinamide adenine dinucleotide (NAD) levels, compared to Controls ” observed significantly lower cellular NAD+ levels and impaired mitochondrial function in patients with primary open-angle glaucoma (POAG).
  • Further, higher NAD+ levels were strongly associated with higher mitochondrial function parameters, suggesting increased NAD+ levels are associated with improved energy production and cellular activity.
  • POAG is a condition where pressure builds inside the eye, causing damage to the optic nerve and gradual vision loss.

HKUMed and CityU Scientists Discover Non-invasive Stimulation of the Eye for Depression and Dementia

Retrieved on: 
Friday, July 8, 2022
Mouse, Patient, City University of Hong Kong, Anxiety, Dementia, Research, Interface (computing), Brain, Gene, Alzheimer's disease, Li Ka Shing Faculty of Medicine, City University, COVID-19, Neuropsychiatric Disease and Treatment, Growth, IBRO Neuroscience Reports, Depression, Ageing, World, DOI, Major depressive disorder, New, World Health Organization, Grammatical mood, Learning, University, Hippocampus, Eye, Science, Animal, Associate, Infection, Prefrontal cortex, Safety, University of Hong Kong, Multimedia, Lists of diseases, SCI, Pharmaceutical industry, Medical device, Medicine

They discovered that non-invasive stimulation of the corneal surface in the eye that activates brain pathways, resulted in remarkable antidepressant-like effects and also reduced stress hormones in an animal model of depression.

Key Points: 
  • They discovered that non-invasive stimulation of the corneal surface in the eye that activates brain pathways, resulted in remarkable antidepressant-like effects and also reduced stress hormones in an animal model of depression.
  • This technique called transcorneal electrical stimulation also induced the expression of genes involved in the development and growth of brain cells in the hippocampus.
  • The application of this non-invasive stimulation of the eye brings new hope for those with depression and dementia.
  • These significant findings were recently published in Brain Stimulation and Annals of the New York Academy of Sciences .

HKUMed and CityU Scientists Discover Non-invasive Stimulation of the Eye for Depression and Dementia

Retrieved on: 
Friday, July 8, 2022
Mouse, Patient, City University of Hong Kong, Anxiety, Dementia, Research, Interface (computing), Brain, Gene, Alzheimer's disease, Li Ka Shing Faculty of Medicine, City University, COVID-19, Neuropsychiatric Disease and Treatment, Growth, IBRO Neuroscience Reports, Depression, Ageing, World, DOI, Major depressive disorder, New, World Health Organization, Grammatical mood, Learning, University, Hippocampus, Eye, Animal, Associate, Infection, Prefrontal cortex, Safety, University of Hong Kong, Science, Lists of diseases, SCI, Pharmaceutical industry, Medical device, Medicine

Major depression is the most common and severe psychiatric disorder across the world.

Key Points: 
  • Major depression is the most common and severe psychiatric disorder across the world.
  • They discovered that non-invasive stimulation of the corneal surface in the eye that activates brain pathways, resulted in remarkable antidepressant-like effects and also reduced stress hormones in an animal model of depression.
  • The application of this non-invasive stimulation of the eye brings new hope for those with depression and dementia.
  • These significant findings were recently published in Brain Stimulation and Annals of the New York Academy of Sciences .

SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China

Retrieved on: 
Monday, July 4, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Department, Pharmacy and Poisons Board, Pharmacy, Influenza A virus subtype H1N1, School, Admission, CEO, RNA transfection, Adult, Research, GHK, Trial of the century, Polio, Li Ka Shing Faculty of Medicine, Wong Chuk Hang, Infection, COVID-19, Immunization, Â, Sinovac Biotech, Department of Medicine – University of Pamplona, HKU, Omicron, School of Clinical Medicine, University of Cambridge, LKS, Viral hepatitis, Asia-Pacific, Campus Biotech, IHH Healthcare, Poison, Clinical trial, NWS Holdings, University, IRB, Virus, Pyaar Tune Kya Kiya (TV series), Animal, Vaccine, Chickenpox, Safety, University of Hong Kong, Vaccination, EV71, Immunity, Faculty, Mumps, Bed, Multimedia, International business, Volunteering, Pharmaceutical industry, Medicine, Gleneagles Hospital

This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.

Key Points: 
  • This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.
  • The University of Hong Kong Clinical Trials Centre (HKU-CTC) is a one-stop clinical research management platform dedicated to facilitating the professional conduct of clinical research projects under HKUMed.
  • As Hong Kongs top-notch private teaching hospital, Gleneagles also contributes to the training and development of healthcare professionals and advancement of clinical research.
  • Gleneagles is a joint venture between IHH Healthcare and NWS Holdings Limited, with The University of Hong Kong as its exclusive clinical partner.

CUHK Professor Elaine Chow Receives "2022 Women's Interprofessional Network of the American Diabetes Association Abstract Award" for Outstanding Research and Care in Diabetes

Retrieved on: 
Sunday, June 5, 2022
Woman, GKA, ADA, List of universities in China, World Diabetes Day, Patient, Faculty, Trial of the century, T2D, Li Ka Shing Faculty of Medicine, Chinese, Public health, Chinese University of Hong Kong, WIN, Education, Pharmaceutical industry, Epidemiology, Medicine

The WIN ADA abstract award category of Clinical Diabetes, Epidemiology, and Diabetes Complications is an important part of WIN ADA awards, voted by WIN ADA Advisory Group, consisting of expert clinicians, scientists, educators, public health practitioners, and other diabetes professionals.

Key Points: 
  • The WIN ADA abstract award category of Clinical Diabetes, Epidemiology, and Diabetes Complications is an important part of WIN ADA awards, voted by WIN ADA Advisory Group, consisting of expert clinicians, scientists, educators, public health practitioners, and other diabetes professionals.
  • It honours women who have made significant contributions to the diabetes research, clinical care, public health, education, and related areas worldwide.
  • The award was presented to Professor Elaine on June 3, 2022.
  • Professor Elaine will present a clinical study called SENSITIZE, which explored the effects of dorzagliatin, the global first-in-class drug, glucokinase activator (GKA) at the ADA Annual Scientific Sessions.